稳定激素治疗中跨性别成人的血液学参考区间
该研究纳入接受睾酮(n=79)或雌激素(n=93)治疗至少12个月的健康跨性别个体,评估血红蛋白、血细胞比容、MCV、MCHC、RDWCV及红细胞、白细胞、血小板计数,并与顺性别参考区间比较。结果显示,无论血清激素浓度如何,接受睾酮或雌激素治疗的跨性别者血液学参数分别与顺性别男性或女性无临床差异。
要点
- 跨性别男性应参照顺性别男性参考区间评估血液学参数。
- 跨性别女性应参照顺性别女性参考区间评估血液学参数。
- 评估时无需同时检测性激素水平。
核心结论
- 接受稳定激素治疗的跨性别男性和女性的血液学参数应分别参照顺性别男性和顺性别女性的参考区间进行评估。
- 评估血液学参数时不需要同时进行性激素分析。
研究设计与样本
- 研究纳入接受睾酮(n=79)或雌激素(n=93)治疗至少12个月的健康跨性别个体,从专注于跨性别医疗的内科和初级保健诊所招募。
- 评估血红蛋白、血细胞比容、MCV、MCHC、RDWCV浓度以及红细胞、白细胞和血小板计数。
- 结果参照总体数值分布及血清雌二醇和总睾酮浓度进行解读,并与已建立的顺性别参考区间比较。
主要发现
- 无论血清激素浓度如何,接受睾酮或雌激素治疗的个体血液学参数分别与顺性别男性和女性无临床差异。
临床怎么用
- 临床解读跨性别者血液学实验室值时,可直接采用其性别认同对应的顺性别参考区间。
- 无需常规检测性激素以辅助血液学参数解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The complete blood count (CBC) is a cornerstone of patient care. Several of the normal values for the components of the CBC differ by sex and, therefore, male-specific and female-specific reference intervals are required to interpret these laboratory results. Transgender individuals are often prescribed hormone therapy to affirm their gender, with resulting serum hormone concentrations similar to those of cisgender individuals. Gender-specific reference intervals for transgender men and women have not been established for any laboratory measurements, including hematology. We established clinically relevant hematological reference intervals for transgender individuals receiving stable hormone therapy. METHODS: Healthy transgender individuals prescribed testosterone (n = 79) or estrogen (n = 93) for ≥12 months were recruited from internal medicine and primary care clinics that specialize in transgender medical care. Concentrations for hemoglobin, hematocrit, MCV, MCHC, and RDWCV, as well as counts for red cells, white cells, and platelets, were evaluated. Results were interpreted in reference to the overall distribution of values and relative to serum estradiol and total testosterone concentrations. Calculated reference intervals were compared to established cisgender reference intervals. RESULTS: Regardless of serum hormone concentration, individuals prescribed testosterone or estrogen had hematology parameters that were not clinically different from cisgender males and females, respectively. CONCLUSION: The hematology parameters for transgender men and women receiving stable hormone therapy should be evaluated against the cisgender male and cisgender female reference ranges, respectively and does not require concurrent sex hormone analysis. Care providers can utilize this observation to aid in interpretation of hematology laboratory values for transgender people.
引用
- Greene DN, McPherson GW, Rongitsch J, et al. Hematology reference intervals for transgender adults on stable hormone therapy. Clin Chim Acta. 2019. PMID: 30771301. doi:10.1016/j.cca.2019.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。